



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Eohilia (budesonide suspension)

Page: 1 of 2

Effective Date: 2/13/2025

Last Review Date: 1/2025

Applies to: ☒ Illinois
☒ Maryland

☒ New Jersey
☒ Florida Kids

☒ Pennsylvania Kids
☒ Virginia

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Eohilia (budesonide suspension) under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Eohilia is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE).

Limitations of Use

Eohilia has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks.

Applicable Drug List:

Eohilia

Policy/Guideline:

Criteria for Approval:

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has the diagnosis of eosinophilic esophagitis (EoE). Documentation is required for approval.

AND

- The patient is 11 years of age or older

AND

- The request is NOT for continuation of therapy

AND

- The patient has a history of clinical symptoms of esophageal dysfunction (e.g., eating problems, abdominal pain, heartburn, dysphagia, vomiting, food impaction, weight loss) at baseline

OR

- The request is for continuation of therapy

AND

- The patient has achieved or maintained a positive clinical response (e.g., improvement in symptoms of esophageal dysfunction, histologic remission on biopsy). [Documentation is required for approval.]



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Eohilia (budesonide suspension)		Page:	2 of 2
Effective Date:	2/13/2025		Last Review Date:	1/2025
Applies to:	☒ Illinois	☒ New Jersey	☒ Pennsylvania Kids	
	☒ Maryland	☒ Florida Kids	☒ Virginia	

Approval Duration and Quantity Restrictions:

Initial Approval: 6 months

Renewal Approval: 12 months

Quantity Level Limit: 60 single-dose stick packs per 30 days

References:

1. Eohilia [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; May 2024.
2. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed August 6, 2024.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 08/06/2024).
4. Dellon E, Gonsalves N, Hirano I, et al. ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE). Am J Gastroenterol. 2013;108(5):679–692.
5. Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology. 2020;158(6):1776-1786.